Assessment of Mortality Stratified by Meropenem MIC in Patients with Enterobacteriaceae Bacteremia: A Patient-level Analysis of Published Data.
In 2010, the Clinical and Laboratory Standards Institute lowered carbapenem breakpoints to reduce the proportion of "susceptible" organisms that produced carbapenemases. Few studies have evaluated the effect of this change on clinical outcomes. PubMed was searched through March 2019 with the terms "carbapenem", "meropenem", "imipenem", "doripenem", "ertapenem", "susceptibility", and "outcomes." Studies were included if patients had an Enterobacteriaceae bacteremia, treated with a carbapenem for ≥48 hours, and reported mortality. Studies were excluded if all isolates were either susceptible or resistant to meropenem based on CLSI 2010 breakpoints or if only carbapenemase-producing isolates were included. Authors were contacted for patient-level data. The primary outcome was 30-day mortality, with planned subset analyses of patients treated with meropenem, received active combination therapy, treated in ICU, or infected with Klebsiella pneumoniae. Of 157 articles identified, four met inclusion criteria for a total of 115 eligible patients. Odds of mortality were increased with each increasing meropenem MIC dilution (OR 1.51, 95%CI: 1.06-2.15) as a continuous variable. A similar increase in odds was observed in patients treated with meropenem, treated in the ICU, infected with K. pneumoniae or received no other active antimicrobials. Increasing meropenem MICs in Enterobacteriaceae were associated with increased mortality; however, more work is needed to define optimal clinical decision rules for infections within the susceptible range.